跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 13,549 条关于
“HLB Co.”
全部
13,549
临床试验
3,673
药物
1,459
机构
1,537
资讯
6,880
去年
FDA Rejects Hengrui-HLB Liver Cancer Combination Therapy for Second Time
上个月
HLB Reports Sharp Revenue Decline and Widening Losses in H1 2025 Amid Oncology Pipeline Push
上个月
Elevar Therapeutics to Present Three Abstracts at ESMO 2026, Including Phase 2 THRIVE Trial of Rivoceranib in Thymic Tumors
2个月前
HLB's Liver Cancer Drug Rivoceranib Hits Third FDA Setback Over Manufacturing Compliance Issues
去年
FDA Accepts Rivoceranib and Camrelizumab Combination for Liver Cancer
去年
FDA Accepts Resubmission of Rivoceranib and Camrelizumab for Liver Cancer
3天前
Elevar Submits EMA Marketing Authorization Application for Lirafugratinib in FGFR2-Fusion Cholangiocarcinoma
2个月前
FDA Issues Complete Response Letter for Elevar's Rivoceranib-Camrelizumab Combination in First-Line HCC
去年
HLB Advances Cancer Drug Pipeline: Rivoceranib FDA Decision Due March, Plans RLY-4008 Development
去年
HLB Group to Resubmit Riboceranib for FDA Approval Following Second Rejection
第 1 页,共 688 页
上一页
下一页